Reuters logo
BRIEF-Morphosys starts Phase 2 trial of MOR208 in combination with idelalisib
December 13, 2016 / 11:23 AM / a year ago

BRIEF-Morphosys starts Phase 2 trial of MOR208 in combination with idelalisib

Dec 13 (Reuters) - Morphosys Ag

* Morphosys starts Phase 2 trial of MOR208 in combination with idelalisib in patients with relapsed or refractory CLL or SLL previously treated with a BTK inhibitor Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below